Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-2131
- Development stage
- Preclinical
- Lead developer
- Addpharma
01
Overview
AD-2131 is an investigational drug developed by Addpharma, primarily targeting digestive system disorders. Its current global highest R&D status is listed as "Pending," and it has been the subject of clinical studies comparing its safety, pharmacokinetics, and pharmacodynamics to a related compound (AD-213-A) in healthy volunteers. Specific details regarding its mechanism of action, molecular target(s), or chemical class have not been disclosed in publicly available sources[1][2][3][5].
Beyond the preview
Go deeper on AD-2131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-2131.